A newly launched UK biotech is looking to develop a new approach to immunotherapy, based around a seemingly paradoxical idea that stimulating cancer makes them more visible to the body’s de
SMi reports: Reyk Horland, Vice President, Business Development at TissUse GmbH to discuss “Applying Multi-Organ-on-a-Chip Technologies for Predictive Substance Testing" at SMi’s Drug Discovery con
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
